newsfilter
← Latest News
Business Wire·

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 – – Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission